Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping Track: Immunocore Wins Nod For First T-Cell Receptor Therapeutic; Veklury And Nucala Expand Settings Of Use; Merck & Co. Strikes Out In Chronic Cough

Executive Summary

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

You may also be interested in...



Japan Lifts Decades-Old Bans On Somatropin In Diabetes, IFNβ In Pregnancy

Japan cautiously lifts decades-old bans on somatropin’s use in diabetic patients and interferon beta 1a/1b in pregnant patients, judging benefits can outweigh risks and following requests from doctors and pharma firms to consider patients.

J.P. Morgan Day 3: First TCR Therapy On The Horizon, Asian Firms Make Their Mark

Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming and new updates from multiple Asian companies. 

Novel Sickle Cell Treatment Among 13 New Drugs On Track For EU Approval

A first-of-its-kind drug for uterine fibroids and a new monoclonal antibody treatment for COVID-19 are among several new drugs recommended for pan-EU approval this month.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel